Model for End-Stage Liver Disease (MELD) exception for hepatic encephalopathy

Liver Transplantation

Volumn 12, Issue 12 SUPPL. 3, 2006, Pages

  Ham, John ^a   Gish, Robert G ^b   Mullen, Kevin ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID; LACTULOSE; METRONIDAZOLE; NEOMYCIN; RIFAXIMIN;

ARTICLE; BRAIN EDEMA; DEHYDRATION; DISEASE ASSOCIATION; GRAFT RECIPIENT; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; PATIENT COMPLIANCE; PORTOSYSTEMIC ANASTOMOSIS; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; REHYDRATION; SEPSIS; SURGICAL MORTALITY; TREATMENT FAILURE;

HEPATIC ENCEPHALOPATHY; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX; TISSUE AND ORGAN PROCUREMENT;

EID: 33845487559     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20968     Document Type: Article

References (12)

1. Adler M, Verset D, Bouhdid H, Bourgeois N, Gulbis B, Le Moine O, et al. Prognostic evaluation of patients with parenchymal cirrhosis. Proposal of a new simple score. J Hepatol 1997;26:642-649.
2. Scientific Registry of Transplant Recipients. Data Analysis for the OPTN Liver-Intestine Committee. Richmond, VA: UNOS; April 5, 2005:264-268.
3. Yoo HY, Edwin D, Thuluvath PJ. Relationship of the Model for End-Stage Liver Disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am J Gastroenterol 2003;98:1395-1399.
4. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: 464-470.
5. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903.
6. Cooper GS, Bellamy P, Dawson NV, Desbiens N, Fulkerson WJJ, Goldman L, et al. A prognostic model for patients with end-stage liver disease. Gastroenterology 1997;113: 1278-1288.
7. del Olmo JA, Pena A, Serra MA, Wassel AH, Benages A, Rodrigo JM. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000;32:19-24.
8. Donovan JP, Schafer DF, Shaw BWJ, Sorrell MF. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet 1998;351:719-721.
9. Jalan R, Dabos K, Redhead DN, Lee A, Hayes PC. Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1997;27:928-933.
10. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978;23:398-406.
11. Ong JP, Mullen KD. Hepatic encephalopathy. Eur J Gastroenterol Hepatol 2001;13:325-334.
12. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721.